In recent years, the importance of the quadruple therapy so-called “fantastic four” used as OMT for HF, namely beta-blockers, angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors, has been widely demonstrated [25]. The gene discussed is SLC5A2; the disease is hydrops fetalis.